Introduction:
Product Name: Alpha GPC powder 50%
CAS No.: 28319-77-9
Molecular Formula: C8H20NO6P
Packing: 1kg/bag or 25kg/Drum with PE bag liner
Shelf Life: 2 Years
L-Alpha Glycerylphosphorylcholine (Alpha GPC, choline alfoscerate) CAS NO.: 28319-77-9 is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have potential for the treatment of Alzheimer's disease and is used as a nootropic dietary supplement to enhance memory and cognition.
L-α-glycerophosphatidylcholine (GPC) is the simplest phospholipid, and an intermediate metabolite in the choline pathway. In addition, GPC serves as an organic osmolyte in the kidney and may play a role in sperm motility. In diet, it is normally presented in low amounts
Function:
Alpha GPC 28319-77-9 increase a chemical in the brain called acetylcholine. This brain chemical is important for memory and learning functions
In Europe alpha-GPC is a prescription medication for the treatment of Alzheimer s disease. It is available in two forms; one is taken by mouth, and the other is given as a shot. In the United States alpha-GPC is only available as a dietary supplement, mostly in products promoted to improve memory.Other uses for alpha-GPC include treatment of various kinds of dementia, stroke, and "mini stroke" (transient ischemic attack, TIA). Alpha-GPC is also used for improving memory, thinking skills, and learning.
Alpha GPC rapidly delivers choline to the brain across the blood-brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter. Alpha GPC is derived from highly purified soy lecithin.
Alpha GPC or GPC has been documented extensively by published studies in both animals and humans to contribute to at least five (5) signt human health functions.
Application:
Alpha GPC 28319-77-9 rapidly delivers choline to the brain across the blood-brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter.Alpha GPC is derived from highly purified soy lecithin by companies like Lipoid, VAV Life Sciences, Chemi SPA etc.
Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer's Disease. An Italian multicentre clinical trial on 2,044 patients suffering from recent stroke were supplied alpha-GPC in doses of 1,000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance.
Commonly used doses are 300-1,200 mg daily.